Landing Page CRO for Peptide Stores: What You Can Test, What You Can’t, and Why

How do you do conversion rate optimisation on a peptide store without creating compliance risk?

Optimise everything except the claims. On a peptide store you can freely test clarity, trust signals, pricing transparency, navigation, page speed and checkout friction, but you should not test copy that describes benefits, effects, human use or dosing — because Google, payment underwriters and FDA all read the landing page, and FDA’s 2026 warning letters treated exactly that kind of copy as evidence of intended human use, even on sites with “research use only” disclaimers.

Conventional CRO advice says to lead with benefits, add social proof, create urgency and remove friction. For most categories that is sound. For peptides, the first two are where policy and legal risk concentrate, and the third can collide with Google’s destination rules. The fourth — removing friction — is where most of the safe opportunity sits.

Who reads a peptide landing page besides the customer?

Reader	What they check	What a bad test variant can trigger
Google (AdsBot and policy review)	Destination requirements, misrepresentation, healthcare and unapproved substances, Merchant Center site requirements	Ad or product disapprovals; account warnings; for misrepresentation, suspension on detection
Payment underwriters and acquirers	Claims, product mix, policies, business identity, consistency with the application	Reserve increases, account review, termination
Regulators (FDA, FTC, state boards)	Intended use, as shown by labelling — which includes website copy	Warning letters with a 15-working-day response window

A test that runs on 50% of traffic for three weeks is still published content. Any of these readers can land on the variant. Our site remediation checklist covers the baseline a page should meet before you start testing anything.

What did FDA’s 2026 warning letters actually quote?

The letters are worth reading directly, because they show that “research” framing did not protect the copy. From two of them:

• Warning letter 721806 (31 March 2026) quoted product-page copy including “Studied for its ability to lower glucose and support balanced insulin levels” and “Associated with significant decreases in body weight in both animal and human studies,” and noted the site used coded names (“GLP-2 peptide”) for tirzepatide. It also said selling bacteriostatic water alongside the peptides showed intent for it to be used for injection.
• Warning letter 734884 (24 August 2026) quoted a comparison blog post listing “Benefits of Tirzepatide” including “Promotes sustainable weight loss,” mechanistic product copy, and, for another product, “Advanced Research Use: Mitochondrial repair, anti-aging, neuroprotection.” It said bacteriostatic water marketed alongside a “peptide guide” and “peptide calculator” collectively provided “the means to prepare an injectable drug for human administration.”

Both letters acknowledged the sites’ “research use only” and “not for human consumption” statements and then concluded that the website evidence established intended human use anyway. For CRO, the lesson is concrete: blog posts, comparison pages, calculators and bundles count as landing-page content. Our Unapproved Substances guide covers how Google treats products under regulatory action.

Which common CRO tactics create risk on peptide pages?

CRO tactic	Why it is risky here	Safer alternative to test
Benefit-led headline (“support fat loss,” “recovery”)	Drug-claim language for FDA; healthcare and unreliable-claims issues for Google	Specification-led headline: compound, quantity, form, purity method, batch testing
“Studied for” or “research shows” summaries	Quoted by FDA as drug claims despite research framing	Link to the certificate of analysis; no efficacy summaries
Customer reviews and testimonials	Reviews that describe personal results are claims you publish	Moderate for results language, or show reviews about shipping, packaging and service only
Dosing guides, reconstitution calculators	Cited by FDA as means to prepare an injectable for human use	Remove; document handling and storage specifications only
Bundles with bacteriostatic water and syringes	Cited by FDA as evidence of intended injection	Unbundle; review whether these items belong in the catalogue at all
Coded or look-alike product names	Noted by FDA; Google bans names “confusingly similar” to unapproved substances	Accurate compound names; if the name itself is the problem, the product is the problem
Countdown timers, full-screen pop-ups, exit-intent overlays	Destination experience policy: pop-ups or interstitials that interfere with seeing the content, or interfere with the back button	Inline offers that do not cover content; easy-to-dismiss banners
Subscribe-and-save with small-print renewal terms	Misrepresentation: dishonest pricing requires clear disclosure of the payment model and full cost	Show renewal price, interval and cancellation path next to the button
Hard age gate or bot-blocking interstitial	Destination not crawlable or not working if AdsBot cannot reach content; blocking crawlers is listed under abuse of the network in Merchant Center	Soft confirmation that does not hide content from crawlers; test with AdsBot user agent

What can you safely test on a peptide landing page?

These areas carry little policy risk and are usually where friction lives:

1. Business identity. Visible business name, contact methods and policy links above the fold. Google’s misrepresentation policy is partly about not obscuring who you are.
2. Certificate of analysis access. Where the COA sits, how quickly it opens, whether it shows lab name, batch and test date, and whether the batch on the COA matches what is shipped.
3. Price and total cost. Showing shipping, taxes and any subscription terms before checkout rather than at the last step.
4. Shipping and returns clarity. Dispatch times, carriers, destinations served, and a returns policy that matches the one in Merchant Center.
5. Information architecture. A consistent specification table across products; category and search structure that helps a buyer find the exact compound and quantity.
6. Speed and stability. Page weight, image formats, third-party scripts. Google’s destination rules cover pages that do not load quickly on common browsers and devices.
7. Checkout friction. Number of steps, guest checkout, form fields, visible payment methods, error messages.

None of these requires saying anything new about what a product does. That is the test for whether a variant belongs on this list.

How should a peptide store run tests without creating policy risk?

1. Review every variant before it goes live against the same checklist you would use for an appeal. If you would not show it to a Google reviewer, do not show it to 50% of your traffic.
2. Serve the same content to everyone. Never show a clean version to crawlers and a claims version to users. Merchant Center’s abuse-of-the-network policy prohibits “manipulating product data or site content in order to bypass our automated system checks,” and Google Ads treats circumvention as egregious.
3. Keep final URLs stable. Destination mismatch rules cover redirects to a different domain and tracking templates that lead to different content. Split tests that redirect across domains can trip them.
4. Decide the sample and the stopping rule before starting, and measure on completed purchases rather than clicks or add-to-carts alone.
5. Keep a dated log of variants. If you are ever asked what a page said on a given date — by Google in an appeal, or by a regulator — you want the answer on file. Our appeal guide explains why dated evidence matters.

If you want a view of where your pages stand before you start testing, the Readiness Score takes about five minutes. For a page-by-page review, book a strategy call.

Sources

• U.S. FDA — Warning letter 721806 (31 March 2026) and Warning letter 734884 (24 August 2026)
• Google Advertising Policies Help — Destination requirements, Destination experience, Destination not accessible
• Google Advertising Policies Help — Misrepresentation (unreliable claims, dishonest pricing practices)
• Google Merchant Center Help — Abuse of the network and Healthcare and medicines

Checked 2026-09-27. This is not legal advice; have counsel review product copy.

Frequently asked